Investor Relations

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA® and ISTODAX®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs® compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to our leading oral anti-inflammatory agents and cellular therapies. We believe our commercial stage products and the depth of our product pipeline, provide the catalysts for future growth.


  • Current Quote
  • Stock Charts
NASDAQ: CELG
123.38
+ 0.16 (0.13%)
Day High: 124.13
Day Low: 122.95
Volume: 2,845,493
4:00 PM ET on Mar 24, 2017
Delayed at least 20 minutes.